Congrats, Priyanka @PriyankaYolmo, for successfully defending your PhD thesis! Very proud of your contributions and this huge accomplishment!

This is happening today! 4 yrs of dedication, hard work, >100 visits to the clinic to collect patient blood samples for her research...many many hours spent in the animal facility, and the novel discoveries she made...excited to hear all about it from @PriyankaYolmo !!!

The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

M cells in the eyes: Allergen uptake from TALT M cells is a major driver of allergic conjunctivitis https://t.co/EPvuATO19n

"Life is the shape it is for a purpose And when you see how things really are all the hurt and the waste falls away What's left is the beauty" Rosalind Franklin, in the "Life Story" movie (1987), especially recommended watching for early career scientists. https://t.co/yqk50FxKDL

And that is a wrap on the AUA-IBCG Bladder Cancer Forum! Thank you to everyone who attended this year and we can’t wait to see you in D.C. next year! @IBCG_BladderCA #AUA25

Inspiring panel at the Basic Science Symposium at #AUA25: “Aging in the Urinary Tract—Advancing Research, Advocacy, and Awareness.” Co-chairs Jill Macoska, PhD and @MysorekarLab challenged panelists to think beyond their labs, highlighting how basic science, clinical needs, and

Was an amazing session and a great meeting #AUA25! Aging remains a major 'unmodifiable risk factor' underlying poor outcomes (+/- BCG) in NMIBC. Thanks to @AmerUrological, for inviting to present our work along the axis of 'immune system aging' and bladder cancer progression!

Excited to share my PhD research in @CR_AACR and at #AACR2025 which elucidates the non-receptor tyrosine kinase Fes as a novel innate immune checkpoint whose deletion enhances innate immunity and sensitizes ICI-resistant tumours to anti-PD1 blockade! @QueensuSCRI @QueensUHealth

Truly deserving of this medal for all her contributions in cancer research and support to several trainees and PIs at DBMS and SCRI! Congrats Gwenaelle (not on twitter)!!! Thanks to @tfri_research for nominating!

Congrats @GSK_UofT @Nimira_A on such a successful & amazing 6th Bladderca forum 🇨🇦 with an all ⭐️ faculty covering key basic/translational science & controversial clinical topics across the spectrum. Thanks for the invitation & warm hospitality!

Save the Date for IBCN's Annual Meeting!! Oct. 9-11, 2025 Munich, Germany

Thank you, Roger @UrogerliMD @MoffittNews for inviting and for the opportunity to discuss our work on B cells and TLSs in bladder cancer Moffitt cancer center, such a happening place with lots of exciting bladder cancer research you are leading…plus the lovely Florida🌞 weather!

Immune cell sequencing from birth to old age "Using our lifecycle-wide single-cell dataset covering 13 age groups over the extent of the human lifespan, we established a comprehensive cross-age index (siAge score) as a type of machine-learning-based immune aging clock to

The IBCG Board is excited to announce the new IBCG Center for Patient-Centric Care Initiatives! This global effort will bring together leading experts, patients, and advocates to explore the multifaceted aspects of patient-centric care with a focus on empowering patients,

https://t.co/WJQi6XxP7x

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. https://t.co/8oRNdVgwZd

This is the most comprehensive integrative omics profiling of >400 NMIBC tumors! A novel integrative clustering defines the iClusters A targetable 'iClus4' with immune exhaustion signature and WGD in most high-grade tumors! Congrats @LDyrskjot and team on another huge milestone!

I interact with a lot of PhDs looking for jobs in biotech. Something I personally think is poorly predictive of thriving as a professional scientist: whether you were in a winner-take-all authorship position on a research article curated by secret reviewers/editors into some

Bladder cancer care is ⬆️⬆️expensive these days 💸. Costs skyrocket from $200K+ for high-risk NMIBC cases to $100K PER tx in advanced dz .. what’s the solution here ? #BladderCancer @EUplatinum @spsutkaMD @UroDocAsh https://t.co/DUQQ9u9vjX